<DOC>
	<DOCNO>NCT00894504</DOCNO>
	<brief_summary>In Phase II trial , investigator evaluate combination gemcitabine , carboplatin , panitumumab treatment patient metastatic triple-negative breast cancer . In addition , assess efficacy combination , tumor tissue examine presence various marker , include K-ras PI3K-activating mutation , EGFR , PTEN , p53 . Correlation tumor response marker expression may define patient subset particularly responsive treatment panitumumab-containing combination .</brief_summary>
	<brief_title>Panitumumab , Gemcitabine Carboplatin Triple-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>All patient receive pre-emptive skin care regimen panitumumab therapy reduce skin toxicity . Treatment cycle repeat every 14 day ( 2 week ) . During treatment , panitumumab administer first , carboplatin , gemcitabine . All drug administer accord standard guideline . Patients re-evaluated response completion 3 cycle ( 6 week ) treatment . Patients objective response stable disease continue treatment . Subsequent re-evaluations occur every 6 week . Patients continue treatment three drug tumor progression , unacceptable toxicity occur . If patient experience toxicity cause gemcitabine/carboplatin continue benefit treatment , panitumumab continue single agent ( dose schedule ) , discretion investigator , disease progression occur .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Female patient &gt; =18 year age . 2 . Histologically cytologically confirm diagnosis unresectable locally advanced stage IV breast cancer . 3 . No 1 prior treatment regimen metastatic breast cancer . 4 . Estrogen receptor progesterone receptor negative ( define &lt; 10 % stain IHC ) . 5 . Paraffinembedded tumor tissue ( primary tumor metastasis ) biomarker test . ( In absence paraffinembedded tissue , unstained paraffinembedded tumor slide acceptable ) . 6 . Measurable disease , define Response Evaluation Criteria Solid Tumors ( RECIST version 1.1 ) guideline 7 . HER2 negative tumor . HER2 negativity must confirm one following : FISHnegative ( FISH ratio &lt; 2.2 ) , IHC 01+ , IHC 23+ AND FISHnegative ( FISH ratio &lt; 2.2 ) 8 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 01 . 9 . Absolute neutrophil count ( ANC ) &gt; =1.5 × 109/L ; platelet count &gt; =100 × 109/L ; hemoglobin &gt; =9.0 g/dL . 10 . Creatinine &lt; =1.5 mg/dL , creatinine clearance &gt; =40 mL/min ( calculate CockcroftGault method , follow : Female creatinine clearance = ( 140 age ) × ( weight kg ) × 0.85 ( serum creatinine × 72 ) 11 . Adequate hepatic function , define follow : total bilirubin &lt; =1.5 x ULN ; aspartate aminotransferase ( AST ) &lt; =3 × ULN ( &lt; = 5 x ULN liver metastasis ) ; alanine aminotransferase ( ALT ) &lt; =3 x ULN ( &lt; =5 x ULN liver metastasis ) . 12 . Magnesium level &gt; = institutional low limit normal ( LLN ) . 13 . Women childbearing potential must agree use adequate contraception ( per institutional standard care ) treatment 6 month last administration investigational product . 1 . Patients brain metastasis eligible . 2 . History another primary cancer , exception following : Curatively treat situ cervical cancer ; Curatively resect nonmelanoma skin cancer ; Other primary solid tumor curatively treat know active disease present treatment administer &gt; =5 year prior study enrollment . 3 . History interstitial lung disease ( e.g. , pneumonitis , pulmonary fibrosis ) , evidence interstitial lung disease CT scan chest perform baseline visit . 4 . Prior antiEGFR antibody therapy ( e.g. , cetuximab ) , treatment smallmolecule EGFR inhibitor ( e.g. , gefitinib , erlotinib , lapatinib ) . 5 . Radiotherapy &lt; =14 day prior study enrollment . Any acute effect radiotherapy must resolve prior administration study drug . 6 . Systemic chemotherapy , hormonal therapy , immunotherapy , experimental approve proteins/antibodies ( e.g. , bevacizumab ) &lt; =21 day prior study enrollment . 7 . Prior therapy gemcitabine carboplatin metastatic setting permit . Patients receive gemcitabine carboplatin part adjuvant therapy eligible , long recurrence first document &gt; 12 month last exposure drug ( ) . 8 . Major surgery within 28 day minor surgery within 14 day study enrollment . 9 . Requirement chronic use immunosuppressive agent ( e.g. , methotrexate , cyclosporine ) . 10 . Any investigational agent therapy &lt; =30 day prior study enrollment . 11 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . 12 . History medical psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation administration investigational product , may interfere interpretation result . 13 . Unwillingness inability comply study requirement . 14 . Women pregnant breastfeeding . 15 . Patients know human immunodeficiency virus ( HIV ) , hepatitis C virus , and/or acute chronic hepatitis B virus infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Triple Negative</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Carboplatin</keyword>
</DOC>